Search

Author/Creator Ahmed, Azazuddin

1. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Issue 10184 (11th May 2019)

Authors:
Heerspink, Hiddo J L; Parving, Hans-Henrik; Andress, Dennis L; Bakris, George; Correa-Rotter, Ricardo; Hou, Fan-Fan; Kitzman, Dalane W; Kohan, Donald; Makino, Hirofumi; McMurray, John J V; Melnick, Joel Z; Miller, Michael G; Pergola, Pablo E; Perkovic, Vlado; Tobe, Sheldon; Yi, Tingting; Wigderso...
Journal:
Lancet
Issue:
Volume 393:Issue 10184(2019)
Page Start:
1937
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial. Issue 6 (19th April 2018)

Authors:
Frías, Juan P.; Hardy, Elise; Ahmed, Azazuddin; Öhman, Peter; Jabbour, Serge; Wang, Hui; Guja, Cristian
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 20:Issue 6(2018)
Page Start:
1520
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study. Issue 6 (4th February 2018)

Authors:
Jabbour, Serge A.; Frías, Juan P.; Guja, Cristian; Hardy, Elise; Ahmed, Azazuddin; Öhman, Peter
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 20:Issue 6(2018)
Page Start:
1515
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Issue 12 (December 2016)

Authors:
Frías, Juan P; Guja, Cristian; Hardy, Elise; Ahmed, Azazuddin; Dong, Fang; Öhman, Peter; Jabbour, Serge A
Journal:
Lancet
Issue:
Volume 4:Issue 12(2016)
Page Start:
1004
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗